Literature DB >> 12524391

Hepatic and extrahepatic malignancies and primary sclerosing cholangitis.

E Schrumpf1, K M Boberg.   

Abstract

Entities:  

Year:  2003        PMID： 12524391      PMCID： PMC1774978          DOI： 10.1136/gut.52.2.165

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  6 in total

Review 1.  Biliary tract cancers.

Authors:  P C de Groen; G J Gores; N F LaRusso; L L Gunderson; D M Nagorney
Journal:  N Engl J Med       Date:  1999-10-28       Impact factor: 91.245

2.  The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis.

Authors:  K M Boberg; A Spurkland; G Rocca; T Egeland; S Saarinen; S Mitchell; U Broomé; R Chapman; O Olerup; A Pares; F Rosina; E Schrumpf
Journal:  Scand J Gastroenterol       Date:  2001-08       Impact factor: 2.423

3.  Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

Authors:  K M Boberg; A Bergquist; S Mitchell; A Pares; F Rosina; U Broomé; R Chapman; O Fausa; T Egeland; G Rocca; E Schrumpf
Journal:  Scand J Gastroenterol       Date:  2002-10       Impact factor: 2.423

4.  Primary sclerosing cholangitis in ulcerative colitis--a risk factor for the development of dysplasia and DNA aneuploidy?

Authors:  U Broomé; G Lindberg; R Löfberg
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

5.  The pancreas in primary biliary cirrhosis and primary sclerosing cholangitis.

Authors:  O Epstein; R W Chapman; G Lake-Bakaar; A Y Foo; S B Rosalki; S Sherlock
Journal:  Gastroenterology       Date:  1982-12       Impact factor: 22.682

6.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.

Authors:  Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083
  6 in total
  1 in total

1.  LTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumours.

Authors:  Anthony J Scarzello; Qun Jiang; Timothy Back; Hien Dang; Deborah Hodge; Charlotte Hanson; Jeffrey Subleski; Jonathan M Weiss; Jimmy K Stauffer; Jitti Chaisaingmongkol; Siritida Rabibhadana; Mathuros Ruchirawat; John Ortaldo; Xin Wei Wang; Paula S Norris; Carl F Ware; Robert H Wiltrout
Journal:  Gut       Date:  2015-07-23       Impact factor: 23.059
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.